| 中文摘要 |
本報告以固相萃取及甲基衍生化方法來分析尿中大麻代謝物11-nor-9-carboxy-Δ9-tetrahydrocannabinol （9-THC-COOH），用以判定受檢者是否使用大麻。d3-9-THC-COOH為內標準品，並以氣相層析質譜儀中之離子監測法（selected ion monitoring）做定性及定量分析。監測9-THC-COOH離子為m／Z 313, 357, 372； d3-9-THC-COOH離子為m／z 316, 360, 375。5 mL空白尿液配製濃度15 ng／mL之9-THC-COOH 時，其固相萃取之回收率大於90%。以單點校正方式定量分析，最低可檢濃度為2.09 ng／mL；線性範圍位於4.18 ng／mL-376 ng／mL間；而線性範圍內之日間精密度試驗其變異係數（Coefficient of variation ）為1.49%-8.03%。" |
| 英文摘要 |
A specimen pretreatment procedure, combining solid-phase extraction and methylation, was developed for the analysis of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (9-THC-COOH) in urine for monitoring marijuana exposure. d3-11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (d3-9-THC-COOH) was used as an internal standard, while the now universal selected ion monitoring gas chromatography-mass spectrometry approach was used for detection (m/z 313, 357, 372 and 316, 360, 375 for 9-THC-COOH and d3-9-THC-COOH, respectively) and quantitation (m/z 372 and 375 for 9-THC-COOH and d3-9-THC-COOH, respectively). The effectiveness of the overall procedure was evaluated. One of the extraction columns evaluated achieved > 90% recovery of the analyte in 5-mL drug-free urine fortified with 15 ng/mL 9-THCCOOH. Using the one-point calibration approach, the overall protocol achieved the following analytical parameters: detection limit: 2.09 ng/mL; limit of quantitation: 4.18 ng/mL; upper end of linear range: 376 ng/mL (or better); interday precision: 1.49--8.03% CV in the 4.18-- 376 ng/mL concentration range studied.
本報告以固相萃取及甲基衍生化方法來分析尿中大麻代謝物11-nor-9-carboxy-Δ9-tetrahydrocannabinol （9-THC-COOH），用以判定受檢者是否使用大麻。d3-9-THC-COOH為內標準品，並以氣相層析質譜儀中之離子監測法（selected ion monitoring）做定性及定量分析。監測9-THC-COOH離子為m／Z 313, 357, 372； d3-9-THC-COOH離子為m／z 316, 360, 375。5 mL空白尿液配製濃度15 ng／mL之9-THC-COOH 時，其固相萃取之回收率大於90%。以單點校正方式定量分析，最低可檢濃度為2.09 ng／mL；線性範圍位於4.18 ng／mL-376 ng／mL間；而線性範圍內之日間精密度試驗其變異係數（Coefficient of variation ）為1.49%-8.03%。 |
本站僅提供期刊文獻檢索。
